(7S,9S)-7-[(2R,4S,5R,6S)-4-amino-5-hydroxy-6-methyloxan-2-yl]oxy-6,9,11-trihydroxy-9-(2-hydroxyacetyl)-4-methoxy-8,10-dihydro-7H-tetracene-5,12-dione;[(19S)-10,19-diethyl-19-hydroxy-14,18-dioxo-17-oxa-3,13-diazapentacyclo[11.8.0.02,11.04,9.015,20]henicosa-1(21),2,4(9),5,7,10,15(20)-heptaen-7-yl] 4-piperidin-1-ylpiperidine-1-carboxylate

• 分子结构分类: 有机化合物 - 苯丙烷和聚酮 - 蒽环类药物
• 英文名称: (7S,9S)-7-[(2R,4S,5R,6S)-4-amino-5-hydroxy-6-methyloxan-2-yl]oxy-6,9,11-trihydroxy-9-(2-hydroxyacetyl)-4-methoxy-8,10-dihydro-7H-tetracene-5,12-dione;[(19S)-10,19-diethyl-19-hydroxy-14,18-dioxo-17-oxa-3,13-diazapentacyclo[11.8.0.02,11.04,9.015,20]henicosa-1(21),2,4(9),5,7,10,15(20)-heptaen-7-yl] 4-piperidin-1-ylpiperidine-1-carboxylate
• 化学式: C60H67N5O17
• 分子量: 1130.2
• InChiKey: NVNPKCYNNLSIPM-DXDZKTLNSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.09
• 重原子数：
  82
• 可旋转键数：
  10
• 环数：
  12.0
• sp3杂化的碳原子比例：
  0.48
• 拓扑面积：
  319
• 氢给体数：
  7
• 氢受体数：
  20

文献信息

• THERAPY INVOLVING ANTIBODIES AGAINST CLAUDIN 18.2 FOR TREATMENT OF CANCER
  申请人：Ganymed Pharmaceuticals AG

  公开号：EP2976360A1

  公开（公告）日：2016-01-27
• [EN] THERAPY INVOLVING ANTIBODIES AGAINST CLAUDIN 18.2 FOR TREATMENT OF CANCER<br/>[FR] THÉRAPIE UTILISANT DES ANTICORPS DIRIGÉS CONTRE LA CLAUDINE-18.2 POUR LE TRAITEMENT DU CANCER
  申请人：GANYMED PHARMACEUTICALS AG

  公开号：WO2014146778A1

  公开（公告）日：2014-09-25

  The present invention generally provides a therapy for effectively treating and/or preventing diseases associated with cells expressing CLDN 18.2, in particular cancer diseases such as gastroesophageal cancer. Data are presented demonstrating that administration of an anti-CLDN18.2 antibody to human patients with gastroesophageal cancer is safe and well-tolerated up to a dose of at least 1000 mg/m2. Furthermore, data are presented demonstrating that the antibody is fully functional in these patients to execute anti-tumor cell effects and evidence for antitumoral activity was obtained.